Clinical trials: Anti-vascular Endothelial Growth Factor
Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.
- Trial name
- NCT01535950
- Testing
- LFG316
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Diabetic Macular Edema
Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
The dexamethasone 700 μg intravitreal implant (DEX-I) delivers dexamethasone gradually to the retina over time. It is an approved drug for the treatment of DME.
- Trial name
- P23-380 - INIT (NCT05978622)
- Where
- 54 sites in Belgium, China and 7 more
- Volunteers
- 236 people
- Sponsor
- AbbVie
Diabetic Macular Edema
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema
To determine if there is visual benefit with Ozurdex treatment every three months compared to monthly anti-VEGF alone, in subjects with persistent diabetic macular edema.
- Trial name
- NCT02036424
- Testing
- Ozurdex, Bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Raj K. Maturi, MD
Ophthalmology, Macular Degeneration
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31…
- Trial name
- AURA (NCT01447043)
- Testing
- Ranibizumab
- Where
- 10 sites in Australia, Canada and 8 more
- Volunteers
- 2,609 people
- Sponsor
- Bayer
Solid Tumors
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
hPV19 is a monoclonal antibody (mAb) directed against vascular endothelial growth factor (VEGF). hPV19 binds to human VEGF with unique binding site on VEGF different from that of Bevacizumab(Avastin) and inhibits the binding of…
- Trial name
- NCT03503604
- Testing
- hPV19 mAb, 5-Fluorouracil, Oxaliplatin
- Where
- China
- Volunteers
- 18 people
- Sponsor
- SuZhou Stainwei Biotech Inc.
Diabetic Macula Edema
To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema
Objectives: To compare the efficacy of monotherapy with anti-Vascular Endothelial Growth Factor (ranibizumab or bevacizumab) with combined therapy with anti-Vascular Endothelial Growth Factor and end-point-management grid laser…
- Trial name
- END-DME (NCT02462304)
- Testing
- End-Point-Management grid laser, ranibizumab, Bevacizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
Vitreomacular Interface
Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration
Purpose: To assess the influence of intravitreal anti-vascular endothelial growth factor (anti-VEGF) administration on vitreomacular interface- and retinal morphology in eyes with neovascular age-related macular degeneration…
- Trial name
- NCT03680326
- Testing
- OCT
- Volunteers
- 43 people
- Sponsor
- Hospital Hietzing
Renal Cell Carcinoma, Kidney Cancer
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
The goal of this clinical research study is to learn if the combination of 3 drugs (gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable renal cell carcinoma.
- Trial name
- NCT00496587
- Testing
- Capecitabine, Gemcitabine, Bevacizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Tumors, Neoplasm Metastasis
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
The objective of this study is to assess the safety, tolerability, dose limiting toxicity, and maximum tolerated dose of vatalanib administered orally once daily in combination with capecitabine in patients with advanced cancer.
- Trial name
- NCT00171587
- Testing
- PTK787/ZK 222584 (vatalanib)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Novartis
Retinal Telangiectasis, Coats Disease
Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
Coats disease is a predominantly unilateral progressive retinal vascular disease, characterized by retinal telangiectasias with intra- or subretinal exudate deposits, which can lead to retinal detachment and one-sided blindness.
- Trial name
- COATS-VEGF (NCT03940690)
- Testing
- Anti-VEGF injections of bevacizumab, Laser
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Eye Diseases, Injection Complication
Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections
This study aims to evaluate the effect of topical prophylaxis with brinzolamide-brimonidine fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal injections of anti-vascular endothelial growth…
- Conditions
- Eye Diseases, Injection Complication, Intraocular Pressure
- Trial name
- NCT04523844
- Testing
- Brinzolamide-brimonidine Fixed Combination
- Where
- Greece
- Volunteers
- 47 people
- Sponsor
- General Hospital of Athens Elpis
HCC - Hepatocellular Carcinoma
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
This trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the…
- Trial name
- NCT07157969
- Testing
- Lenvatinib, Pembrolizumab, Atezolizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Post-Injection Intraocular Pressure Spikes
Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy
In this study, investigators will be examining the intraocular pressure lowering effect of brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.
- Trial name
- NCT03513172
- Testing
- topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Wet AMD
Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.
- Trial name
- NCT01310686
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- West Coast Retina Medical Group, Inc.
Wet Macular Degeneration
Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of…
- Trial name
- MACBETH (NCT01896284)
- Testing
- 0.5mg aflibercept
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Barcelona Macula Foundation
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
This was the cross-sectional study to assess the period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019.
- Trial name
- NCT05146687
- Testing
- Aflibercept, Ranibizumab, Bevacizumab
- Where
- United States
- Volunteers
- 369,600 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
The study will investigate changes in the structure and function of blood vessels in the front and back of the eye following laser and anti-VEGF treatments for sight-threatening diabetic eye disease.
- Trial name
- VEGF (NCT01196325)
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth…
- Conditions
- Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT05110118
- Testing
- LY01008, Avastin
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Diabetic Macular Edema, Cataract
Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery
The investigators aim to evaluate how different timing of anti-VEGF intravitreous injections affect visual acuity (BCVA) in patients with diabetic macular edema who are undergoing cataract surgery; and to evaluate how different…
- Trial name
- Anti-VEGF (NCT04063358)
- Testing
- Lucentis
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Military Medical University